Post-doctoral position
Structure: UMR 915-Institut du thorax, Team IIa “Signaling and hypertension” (www.umr915.univ-nantes.fr)
Location: Nantes, France
Contract: 18 to 36 months
Immediately available
We are looking for a highly motivated postdoctoral scientist to join the “Signaling and Hypertension” team that investigates the role of Rho proteins in vascular smooth muscle cells and their involvement in arterial diseases.
The research project will focus on the characterization of the role of the Rho protein Rac1 in the cardiovascular system, in arterial smooth muscle and endothelial cells. Both cell and animal models will be used to perform gene/function analyses by several approaches including molecular biology, biochemistry, cell biology and functional studies.
The successful applicant should have a PhD in biochemistry/cell biology and physiology/molecular biology with strong motivation and interest in cell signaling.
Ideal candidates will have good skills in biochemistry (protein extraction, western blot, immunoprecipitation), in molecular and cellular biology, transfection and cell culture. Experience in physiology (animal experimentation) and in cardiovascular area will be an advantage.
Interested applicants should submit a CV (which lists at least 2 references) and a brief letter (1 page) outlining prior research experience and personal research interests.
Contact: Vincent SAUZEAU
Phone: +33-2 28 08 01 75
e-mail: vincent.sauzeau@inserm.fr
Main recent publications:
1- Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol. 2010 Nov;7(11):637-47.
2- Sauzeau V, Berenjeno IM, Citterio C, Bustelo XR. A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton. Oncogene. 2010.
3- Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010 Feb;16(2):183-90.
4- Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest. 2010 Jan;120(1):315-30.
5- Sauzeau V, Jerkic M, López-Novoa JM, Bustelo XR. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell. 2007 Mar;18(3):943-52
6- Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, López-Novoa JM, Bustelo XR. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med. 2006 Jul;12(7):841-5.